Raising the bar for using surrogate endpoints in drug regulation and health technology assessment Post date 16 September 2021 ← Morris Greenberg: occupational health specialist on a lifelong quest to make the world asbestos free → Should regulatory authorities approve drugs based on surrogate endpoints?